Emerging Technology Partners
VC Fund
San Francisco, United States
Emerging Technology Partners is a VC fund in San Francisco focused on Health Care and Biotechnology. Founded in 2000, Emerging Technology Partners (“ETP”) is a life sciences focused investment fund with a cross border investment focus. ETP was founded with a simple mission: to provide capital and assist management in building and commercializing breakthrough diagnostic and therapeutic products in the fields of life sciences, while providingsuperior returns to their investors.ETP supports their portfolio companies facilitate strategic alliances including cross-border partnerships, recruit management, and acquire new products and technologies to accelerate growth in both US and China. They have investment partners in San Francisco, Boston, Washington DC, and Beijing.
- Total investments:
- 17
- Last investment:
- Lead investor:
- 41%
Last updated:
For AI agents: llms.txt
Industries Emerging Technology Partners invests in
Stages Emerging Technology Partners invests in
Countries Emerging Technology Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $1M–$3.5M
- Series A
- $8.3M–$30M
- Series B
- $3.4M–$40M
Investment Focus
Industry
- Health Care 10 (59%)
- Biotechnology 9 (53%)
- Medical 7 (41%)
- Genetics 3 (18%)
- Health Diagnostics 3 (18%)
Stage
- Series A 5 (29%)
- Series B 3 (18%)
- Seed 2 (12%)
- Funding Round 2 (12%)
- Venture - Series Unknown 2 (12%)
Country
- United States 8 (47%)
- China 4 (24%)
- Hong Kong 1 (6%)
- Switzerland 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Wei-Wu He
Founder & General Partner
|
Founder & General Partner | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
Qiu Shui Semiconductor
|
Qiu Shui Semiconductor is a semiconductor company that specialized on Micro-LED display technology.Qiu Shui Semiconductor's core products are Micro-LED micro display chips and modules, which are widely utilized in digital car lighting, micro projection, and augmented reality displays. | $29.6M / Series A / Jun 01, 2026 | |
| CASI Pharmaceuticals, Inc. ("CASI", "we" or "us") is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. CASI is focused on acquiring, developing and commercializing products that augmentits hematology oncology therapeutic focus as well as other areas of unmet medical need. CASI is executing its plan to become a biopharmaceutical leader by launching medicines in the greater China market leveraging CASI's China-based regulatory and commercial competencies and its global drug development expertise. | $20M / Post-IPO Debt / Dec 11, 2025 | ||
| Human Longevity (HLI) is the genomic-based, health intelligence company empowering proactive healthcare and enabling a life better lived. HLI combines the largest database of genomic and phenotypic data with machine learning to drive discoveries and revolutionize the practice of medicine. Its business areas include the HLI Health Nucleus, a genomicpowered clinical research center that uses whole-genome sequence analysis, advanced clinical imaging, and innovative machine learning, along with curated personal health information to deliver the most complete picture of individual health; HLIQ Whole Genome and HLIQ Oncology. It was founded in 2013 and is headquartered in San Diego, California. | $39.8M / Series B / Aug 21, 2024 | ||
Heranova Lifesciences
|
Hekaiwei is a provider of innovative solutions for women's health. | $3.5M / Seed / Dec 28, 2023 | |
|
Precision Autoimmune Therapeutics
|
Precision Autoimmune Therapeutics is a clinical-stage innovative drug development company focused on precision therapeutics for patients with autoimmune and inflammatory diseases. | $20.9M / Venture - Series Unknown / Jul 06, 2022 | |
| Deep Longevity is a biotechnology company transforming longevity R&D through AI-discovered biomarkers of aging using clinical blood tests, transcriptomic, proteomic, epigenetic, microbiome, behavioral, wearable, imaging, and multiple other data types. | Series A / Jul 14, 2020 | ||
| Sun Genomics is a precision nutrition company focused on curing dysbiosis through the gut microflora and personalized solutions. Its flagship product Floré, is a microbiome test and custom synbiotics solution that utilizes whole-genome sequencing to evaluate different digestive system data points and ensure that customers receive a completelypersonalized product based on their unique gut profiles. The company also offers: Floré Tots, Kids, and Baby, available for kids up to age 0-12, and comes in an easy digestive powder to mix with their favorite drink. Floré Clinical, which is specifically for professional practitioners and their patients. Floré Defense, Balance, and Performance for sports teams and athletes. | $9.3M / Series A / Jun 29, 2020 | ||
| Polaris Biology is a medical technology company specializing in the development and clinical application of cell-level precision diagnostic technology, is dedicated to exploring and studying individual and dynamic changes in tumors at the cellular level, and using this information to support clinical tumor diagnosis and treatment. | $9.9M / Series B / Jun 24, 2020 | ||
| SleepScore Labs helps millions of people improve their sleep through unique insights grounded in data and science. The chosen sleep partner of some of the world's leading companies, SleepScore Labs enables them to improve their health & wellness offerings through data and science. A unique technology platform and the leading team in thesleep field support the mission to help hundreds of millions more people sleep better, live better and healthier. | May 01, 2020 | ||
| Sleep.ai is a sleep intelligence company helping digital health, wellness, insurance, and consumer product brands improve sleep outcomes through personalized, science-backed insights. Powered by more than 1B hours of objective sleep data and over 250 scientific studies, Sleep.ai delivers APIs, SDKs, and R&D services that drive measurableimpact, from engagement and retention to health improvement and product differentiation. Its proprietary machine learning models are trained on the world’s largest validated sleep dataset, enabling actionable intelligence across every category influenced by sleep, including metabolic health, mental clarity, recovery, hormonal balance, and more. SleepScore Labs, the company’s internal R&D division, has led all 250+ studies and contributed to over 90 peer-reviewed publications, making Sleep.ai one of the most scientifically validated platforms in the space. The platform operates without requiring wearables, while remaining fully interoperable with third-party devices and health data ecosystems. | Venture - Series Unknown / May 01, 2020 | ||
| See all 17 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Emerging Technology Partners invest in?
Emerging Technology Partners invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 17 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Emerging Technology Partners invest in?
Emerging Technology Partners typically joins rounds of $1M–$3.5M at Seed, $8.3M–$30M at Series A and $3.4M–$40M at Series B. These are whole funding-round sizes, not Emerging Technology Partners's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Emerging Technology Partners took part in.
How do I contact Emerging Technology Partners?
Public channels for Emerging Technology Partners include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Emerging Technology Partners?
The team at Emerging Technology Partners includes Wei-Wu He (Founder & General Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
